Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

ClinicalTrials.gov ID: NCT04460937

Public ClinicalTrials.gov record NCT04460937. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer

Study identification

NCT ID: NCT04460937
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 4 participants

Conditions and interventions

Conditions

Interventions

Adavosertib Drug
Radiation Therapy Radiation

Drug · Radiation

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 8, 2021
Primary completion: Mar 28, 2024
Completion: Dec 17, 2026
Last update posted: Apr 28, 2026

2021 – 2026

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 6

Facility	City	State	ZIP	Site status
City of Hope Comprehensive Cancer Center	Duarte	California	91010	—
Northwestern University	Chicago	Illinois	60611	—
University of Kentucky/Markey Cancer Center	Lexington	Kentucky	40536	—
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	—
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	—
University of Utah Sugarhouse Health Center	Salt Lake City	Utah	84106	—
Huntsman Cancer Institute/University of Utah	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04460937, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 28, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04460937 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →